GLP-1 Therapy for Type 2 Diabetes & Weight Loss
In the last decade, the global rise in metabolic disorders—particularly type 2 diabetes and obesity—has significantly shifted the clinical focus toward proactive, pharmacological interventions grounded in evidence. According to the World Obesity Atlas 2023, over 51% of the global population is projected to be overweight or obese by 2035. The International Diabetes Federation (IDF) estimates that 537 million adults are currently living with diabetes—a number expected to rise to 643 million by 2030.